Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276496 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9ANPC1MAPTKMT2A | |
| SCHEMBL9498449 | 0.86 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9ANPC1MAPTKMT2A | |
| SCHEMBL28285396 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9ANPC1ESR1KMT2A | |
| SCHEMBL370634 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9ANPC1MAPTESR1 | |
| SCHEMBL4314338 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2RAB9ANPC1MAPTKMT2A | |
| SCHEMBL13724404 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2RAB9ANPC1MAPTKMT2A | |
| SCHEMBL5082397 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2KMT2AALDH1A1POLBARG1 | |
| SCHEMBL28413508 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2RAB9ANPC1ESR1KMT2A | |
| SCHEMBL10448571 | 0.80 | TLR8 (0.56) | SMN1; SMN2KMT2AALDH1A1POLBARG1 | |
| SCHEMBL5989122 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9ANPC1ESR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110204494-B | Oxygen-substituted phenylimidazole XOR/URAT1 dual inhibitor and preparation and application thereof | 华南理工大学 | 2023-03-24 | — | — | CN | claimed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | claimed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| CN-102471293-B | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-01 | — | — | CN | claimed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| CN-103596569-A | BACE-2 inhibitors for the treatment of metabolic disorders | NOVARTIS AG | 2014-02-19 | — | — | CN | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| CN-102666507-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2012-09-12 | — | — | CN | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | claimed |
| CN-102471293-A | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG | 2012-05-23 | — | — | CN | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| CN-120137356-A | Degradable epoxy resin composite material, preparation method thereof and degradation method | 深圳市郎搏万先进材料有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119331382-A | Degradable epoxy resin material and degradation method thereof | 深圳市郎搏万先进材料有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-116903825-A | Modified polyurethane acrylate resin, adhesive and preparation method thereof | 上海汉司实业有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-2321319-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| CN-101884131-A | New fuel cell, and power supply device and electronic device using the fuel cell | SONY CORP | 2010-11-10 | — | — | CN | disclosed |
| WO-2010011959-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | SMN1; SMN2 815/4885RAB9A 1227/4885NPC1 28/4885 |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885RAB9A 1694/4885NPC1 516/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | SMN1; SMN2 17/4885RAB9A 4204/4885NPC1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.